Biosketch Xavier Maldonado

Biosketch Xavier Maldonado
Xavier Maldonado
xaviermaldonado@vhio.net
Current position
  • Head of Group, Radiation Oncology Group
  • Head of the Department of Radiation Oncology, Vall d’Hebron University Hospital
  • Vice-president of the National Commission of Radiation Oncology of the National Council of Specialities in Health Sciences of the Ministry of Health, Social Services and Equality.
Honors and Memberships
  • SOCIEDAD ESPAÑOLA DE RADIOTERAPIA Y ONCOLOGIA (S.E.O.R)
  • EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY. (E.S.T.R.O.)
  • AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY (A.S.T.R.O.)
  • EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT CANCER (E.O.R.T.C.)
  • INSTITUTO PARA LA INVESTIGACIÓN EN RADIOTERAPIA (IRAD). Miembro de la junta directiva
Academic Qualifications
  • Degree in Medicine and Surgery from the University of Barcelona, 1989.
  • M.I.R. in Radiotherapy Oncology from 1991 to 1994.
  • PhD in Medicine from the Autonomous University of Barcelona, 2018.
Awards and Recognition

AWARDS:

  • Best Radiation Oncology Service in Spain in 2023 according to the Health Reputation Monitor
  • Second best Radiation Oncology Service by 2022 according to the Health Reputation Monitor
  • Award to one of the three best doctors in Radiation Oncology in Spain in 2024

GRANTS:

  • Grant from the HEALTH RESEARCH FUND ( DART 01/05 ). “Phase III randomised multicentre trial of adjuvant androgen deprivation in combination with high-dose three-dimensional conformal radiotherapy in localised intermediate-high risk prostate cancer” Duration 2005-2006.
  • Grant from the HEALTH RESEARCH FUND (FIS 97/1063) “Evaluation of the response by nuclear magnetic resonance spectroscopy to chemo-radiotherapy treatments in head and neck tumours”.
  • FONDO DE INVESTIGACION SANITARIA grant ( FIS 24/00527) Study of the clinical and biological factors associated with the risk of relapse in intermediate and high risk localised prostate cancer subjected to androgen deprivation and combined radiotherapy.
  • Grant IRAD_SEOR 2024: Role of circulating exosomes as a biomarker for risk stratification and personalisation of treatment in patients with prostate cancer after radical prostatectomy.
Most relevant scientific publications
  1. Artículo científico.  2023.  Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.  ISSN 0732-183X.  https://doi.org/10.1200/JCO.23.00617
  2. Artículo científico. 2022. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. ISSN 1470-2045.  https://doi.org/10.1016/S1470-2045(21)00705-1
  3. Artículo científico.  2022.  Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.  ISSN 1477-7525.  https://doi.org/10.1186/s12955-021-01856-z
  4. Artículo científico.  2022.  High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium.  ISSN 1527-7755.  https://doi.org/10.1200/JCO.22.00970
  5. Artículo científico. 2022. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. ISSN 1470-2045.  https://doi.org/10.1016/s1470-2045(22)00190-5
  6. Artículo científico.  2022.  Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer.  ISSN 2374-2437.  https://doi.org/10.1001/jamaoncol.2021.6871
  7. Artículo científico. 2022. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. ISSN 1527-7755.  https://doi.org/10.1200/JCO.22.00970.
  8. Artículo científico.  2021.  Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. ISSN 0167-8140.  https://doi.org/10.1016/j.radonc.2021.04.018
  9. Artículo científico.  2020.  Genetic testing for the clinician in prostate cancer.  ISSN 1473-7159.  https://doi.org/10.1080/14737159.2020.1816170
  10. Artículo científico. 2015. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.ISSN 1470-2045.  https://doi.org/10.1016/S1470-2045(15)70045-8
All publications
  1. Soumyajit Roy, Tahmineh Romero,Jeff M. Michalski, Felix Y. Feng, Jason Efstathiou, Colleen A.F. Lawton, Michel Bolla, Philippe Maingon,  Theo de Reijke,  David Joseph, Wee Loon Ong, Matthew R. SydesDavid P. Dearnaley, Alison C. Treep ; Nathalie Carrierp Abdenour Nabid, p Luis Souhami,  Luca Incrocci,  Wilma D. Heemsbergen, p Floris J. Pos,pAlmudena Zapatero,  Araceli Guerrero, Ana Alvarez,  Carmen Gonzalez San-Segundo, Xavier Maldonado, Robert E. Reiter,  Matthew B. Rettig,  Nicholas G. Nickols, Michael L. Steinberg, Luca F. Valle, T. Martin Ma, Matthew J. Farrell, Beth K. Neilsen, Jesus E. Juarez, Jie Deng, Sitaram Vangala, Norbert Avril, Angela Y. Jia, Nicholas G. Zaorsky, Yilun Sun, Daniel Spratt and Amar U. Kishan, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023, jul. 12, DOI https://doi.org/10.1200/JCO.23.00617
  2. Maria Antonia Gómez-Aparicio, Fernando López-Campos, Antonio José Lozano, Xavier Maldonado, Begoña Caballero, Juan Zafra, Vladamir Suarez,  Elena Moreno,  Stefano Arcangeli,  Marta Scorsetti,  Felipe Couñago .  Novel Approaches in the Systemic Management of High-Risk Prostate Cancer. Clinical Genitourinary Cancer 2023, Vol. 000, No.xxx, 1–10.  org/10.1016/j.clgc.2023.06.001
  3. Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N,Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus. Clin Transl Oncol. 2022 Nov 27. doi: 10.1007/s12094-022-03005-4. Epub ahead of print. PMID: 36436177.
  4. Ting Martin Ma, MD, Yilun Sun,  Shawn Malone, Mack Roach III, David Dearnaley,; Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall , Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle,; Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, and Amar U. Kishan, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigator. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized. J Clin Oncol. 2023 Feb 1;41(4):881-892. doi: 10.1200/JCO.22.00970.
  5. P.C. Lara ,J I. Rodríguez-Melcón ,A. Palacios ,A. Lozano, A. Hervás-Morón ,Elena  Villafranca ,A. Gómez-Iturriaga ,G. Sancho, X. Maldonado.  Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Frontiers in Oncology, July 2022 | Volume 12 | Article 891886, 1-12. doi: 10.3389/fonc.2022.891886.
  6. Amar U. Kishan, Xiaoyan Wang, Yilun Sun, Tahmineh Romero, Jeff M. Michalski, Ting Martin Ma, Felix Y. Feng, Howard M. Sandler, Michel Bolla, Philippe Maingon , Theo De Reijke, Anouk Neven , Allison Steigler, James W. Denham, David Joseph, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Matt R. Sydes, David P. Dearnaley, Isabel Syndikus, Alison C. Tree, Luca Incrocci, Wilma D. Heemsbergen, Floris J. Pos, Almudena Zapatero, Jason A. Efstathiou, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Michael Xiang, Matthew B. Rettig, Robert E. Reiter, Nicholas G. Zaorsky, Wee Loon Ong, Robert T. Dess, Michael L. Steinberg, Nicholas G. Nickols, Soumyajit Roy, Jorge A. Garciay Daniel E. Spratt High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022-07-01, Volumen 82, Número 1, Páginas 106-114.
  7. Almudena Zapatero PhD, Araceli Guerrero MD, Xavier Maldonado PhD, Ana Álvarez MD, Carmen González San-Segundo PhD, María Ángeles Cabeza Rodríguez MD, Josep María Solé MD, Agustí Pedro Olivé MD, Francesc Casas PhD, Ana Boladeras PhD, Carmen Martín de Vidales PhD, María Luisa Vázquez de la Torre MD, Susana Vara MSc, Juan Luis Sanz MScy Felipe A Calvo PhD. High- dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncology, The, 2022-05-01, Volumen 23, Número 5, Páginas 671-681.
  8. Fernández Rodríguez LJ, Maldonado X. Pineal germinoma in a young adult: a case report.  Cancer Reports 2022; e161, 1-8. Cancer Reports, Wiley. Doi.org/10.1002/cnr2.1611
  9. Fernández-Rodríguez LJ, Arens-Benites M, Maldonado X. (February 24, 2022) Image-Guided Radiation Therapy for Squamous Cell Cancer of the Head and Neck in a Specialized Peruvian Public Hospital. Cureus 14(2):   e22569.  DOI 10.7759/cureus.22569.
  10. Amar U Kishan; Alison Steigler; James Denham; Almudena Zapatero; Araceli Guerrero; David Joseph; Xavier Maldonado; Jessica Wong; Bradley Stish; Robert Dess; Avinash Pilar; Chandana Reddy; Trude Wedde; Wolfgang Lilleby; Ryan Fiano; Gregory Merrick; Richard Stock; D. Jeffrey Demanes; Brian Moran; Phuoc Tran; Santiago Martin; Rafael Martinez Monge; Daniel Krauss; Eyad Abu-Isa; Thomas Pisansky; Richard Choo; Daniel Song; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore DeWeese; Ashley Ross; Jay Ciezki; Derya Tilki; R. Jeffrey Karnes; Jeffrey Tosoian; Nicholas Nickols; Prashant Bhat; David Shabsovich; Jesus Juarez; Tommy Jiang; T. Martin Ma; Michael Xiang; Rebecca Philipson; Albert Chang; Patrick Kupelian; Matthew Rettig; Felix Feng; Alejandro Berlin; Jonathan Tward; Brian Davis; Robert Reiter; Michael Steinberg; David Elashoff; Paul Boutros; Eric Horwitz; Rahul Tendulkar; Daniel Spratt; Tahmineh Romero. The Interplay of Radiotherapy Dose and Androgen Deprivation Therapy Duration for High Risk Prostate Cancer: An Individual Patient Data Analysis of Three Cohorts.  Jama Oncology published online January 20, 2022. doi:10.1001/jamaoncol.2021.6871.
  11. Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost,  Felipe Couñago. Bone health and therapeutics agents in advance prostate cancer. Biosci. (Landmark Ed) 2022 ; 27(1): 034  http://doi.org/10.31083/j.fbl2701034
  12. Kishan AU, Sun y, Pisansky T, Bolla M,Neven A, Steigler A, DENHAM jw, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Soauhamai L, Dune MT, Efstahiou JA, Sandles HM, Guerrero A, Joseph D, Maignon P, De Reijke T, Maldonado X, Martin Ma T, Romero T, Wang X, Retting MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE, the MARCAP Consortium Group. Androgen deprivation therapy use and duration with definitive radiotherapy for localized prostate cancer: an individual patient data meta-analysis. The Lancet Oncology 2022-02-01, Volumen 23, Número 2, Páginas 304-316 https://doi.org/10.1016/S1470-2045(21)00705-1
  13. Almudena Zapatero, Xavier Maldonado, Antonio Gómez Caamaño, José Pardo Masferrer, Víctor Macías Hernández, Asunción Hervás Morón, Julia Luisa Muñoz García, Amalia Palacios Eito, Paloma Anguita-Alonso, Cristina González-Junco, José López Torrecilla1. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: Validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain. Health and Quality of Life Outcomes – 2021 19:223. https://doi.org/10.1186/s12955-021-01856-z (IF 4.011)
  14. Nely Díaz-Mejía, David Garcia-Illescas, Rafael Morales, Cristina Suarez, Jacques Planas, Xavier Maldonado, Joan Carles, Joaquin Mateo. PARP inhibitors in advanced prostate cancer: when to use them?   Endocrine-Related Cancer. dOI: 10.1530/ERC-21-0133 Volume/Issue: Volume 28: Issue 8  , T79–T93 , 15 jul 2021
  15. Almudena Zapatero, Ana Álvarez, MD; Araceli Guerrero, MD; Xavier Maldonado, Md, PhD; Carmen González San Segundo, MD, PhD; María A. Cabeza, MD; Carmen Martín de Vidales, MD, PhD; Josep M. Solé, MD; Agustí Pedro Olivé, MD; Francesc Casas, MD, PhD; Ana Boladeras, MD; María L. Vázquez de la Torre, MD; Susana  Vara, MSc; Felipe. A. Calvo, MD, PhD. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: results from a phase III trial. Radiotherapy and Oncology 2021; 160 (121) 115-119  (IF 2020 5.14)
  16. López Campos F, Sancho Pardo G, Maldonado Pijoan X, Zilli T, Couñago Lorenzo F, Hervás. Is hypofractionation acceptable for prostate bed radiotherapy?  A.Urol Oncol. 2021 Jun;39(6):346-350. doi: 10.1016/j.urolonc.2021.02.002. Epub 2021 Feb 23.PMID: 34049781 (IF 2018 2,82
  17. Fernando López Campos, Estefanía Linares-Espinós, Xavier Maldonado Pijoan, Gemma Sancho Pardo, Todd Mathew Morgan, Claudio Martínez-Ballesteros, Juan Martínez-Salamanca & Felipe Couñago Lorenzo (2020) Genetic Testing for the Clinician in Prostate Cancer, Expert Review of Molecular Diagnostics, DOI: 10.1080/14737159.2020.1816170 (IF 4.096)
  18. Morales R., Suárez C., González M., Valverde C., Serra E., Mateo J., Raventós C., Maldonado X., Morote J., Carles J. The future of bladder Cancer Therapy: Optimizing the inhibition of the fibroblast growth factor recertor. Cancer Treatment Reviews 2020, 86: 1-11. https://doi.org/10.1016/j.ctrv.2020.102000 (IF 2020 8.85)
  19. Maldonado X. Nuevos escenarios en el tratamiento con radioterapia del cáncer de Rev.Cáncer, 2020; Vol. 33, (4), 1-11 (IF 2020 0.014
  20. Guillem V., Algaba F., Arranz JA., Cassinello J., Climent MA., Duran I., Gómez de Liaño A., Maldonado X., Puente J., Rubio J. NCCN Clinical Practice Gudelines in Oncology (NCCN Guidelines). Prostate Cancer. European edition: Spain. Version 2.2019-August 6, 2019. (https://www.nccn.org/global/international_adaptations.aspx (IF 4.589)
  21. Font A., Luque R., Villa JC., Domenech M., Vázquez S., Gallardo E., Virizuela JA., Beato C., Morales-Barrera R., Gelabert A., Macià S., Puente J., Rubio G., Maldonado X., Pérez Valderrama B., Pinto A., Fernández Calv o O., Grande E., Garde Noguera J., Fernández Parra E., Arranz Ja. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with reatment recommendations from the Spanish Oncology GenitoUrinary Group (SOGUG). Targeted Oncology 2019 , https://doi.org/10.1007/s11523-019-00619-7 (IF 4.036)
  22. J.Carles, E.Gallardo, M.Doménech, A.Font, J.Bellmeunt, M.Fígols, B.Mellado, MI Sáez, C.Suárez, MJ Mémdez, P.Maroto, R.Luque, T.Portugal, R.Aldabó, T.bonfill, R.Morales-Barrera, J.García, S.Macía, X.Maldonado, P.Foro. Phase 2 Randomized Study of Radiation Therapy and 3 Year Androgen Deprivation with or without concurrent weekly Docetaxel in High-Risk localized Prostate Cancer Patients. Int J. Radiat oncol Biol Phys, 2019 Vol. 103, Issue 2, 344–352 (IF 2019 5.89
  23. A. Gomez‑Caamano,  C. Gonzalez‑San Segund, I. Henríquez,  X. Maldonado,  A. Zapatero. Consensus on management of castration‑resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR)of the Spanish Society of Radiation Oncology. Clin Transl Oncol 08.oct.2018 https://doi.org/10.1007/s12094-018-1940-2 (IF 2018 2.37)
  24. Juan Morote, Inma Comas, Jacques Planas, Xavier Maldonado, Ana Celma, José Placer, Roser Ferrer, Joan Carles, Lucas Regis. Serum Testosterone Levels in Prostate Cancer Patients Undergoing LuteinizingHormone-Releasing Hormone Agonist Therapy. Clinical Genitourinary Cancer, 2018;16(2):e491-496. https://doi.org/10.1016/j.clgc.2017.10.025 (IF 2.181)
  25. M. Martınez-Garcia, J. Alvarez-Linera, C. Carrato, L. Ley, R. Luque, X. Maldonado, M. Martınez-Aguillo, L. M. Navarro, M. A. Vaz-Salgado, M. Gil-Gil. SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol 30.c0t.2017. DOI 10.1007/s12094-017-1763-6 (IF 2.43)
  26. Manuel Toledo; Silvana Sarria-Estrada; Manuel Quintana; Xavier Maldonado, Francisco Martinez-Ricarte; Jordi Rodon; Cristina Auger; Aizpurua Miren; Javier Salas-Puig; Estevo Santamarina; Elena Martinez-Saez, MD. . Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Research. 130 (2017) 1-6
  27. Giraldo A., Benavente S, Ramos M, Verges R, Coronil O, Arbelaez L, Maldonado X, Altabas M, Molla M, Reyes V, Navalpotro B, Giralt J. Effectiveness of radiotherapy for metastaic spinal cord compresssion in patients with short life expentancy. Reports of Practical Oncology and Radiotherapy 22: 2017; 58-63
  28. Regis L, Planas J, Carles J, Maldonado X, Comas I, Ferrer R, Morote J. Free Testosterone During Androgen Deprivation Therapy Predicts Castration –Resistant Progression Better Than Total Testosterone. Prostate. 2017 Jan;77(1):114-120. doi: 10.1002/pros.23256. Epub 2016 Nov 1.PMID:27800640
  29. F. Casas, I. Henríquez. A. Bejar, X. Maldonado, A. Alvarez,C. González-Sansegundo  A. Boladeras, F. Ferrer, A. Hervás, I. Herruzo, M. Caro, I. Rodriguez, C. Ferrer. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Translat Oncol 2017; 19:373-37
  30. Morales R, Suarez C., Martinez de Castro AM., Racca F., Valverde C., Maldonado X., Bastaros JM, Morote J., Carles J. Targeting fibroblast growth factor receptors and immune check point inhibitors of advanced bladder cancer: New direction and Hope. Cancer Treatment Reviews 50 (2016) 208-2016
  31. Zapatero, A., Guerrero A., Maldonado X., Alvarez A., Gonzàlez Sansegundo C, Cabeza MA., Macias V., Olivé P., Casas F., Boladeras A., Martin de Vidales C., Vázquez de la Torre M., Calvo F. Late Radiation  and cardiovascular adverse effects following androgen deprivation and hihgh dose radiotherapy in prostate cáncer: Results fron DART 01/05 Randomized Phase III trial. Int J. Radiat oncol Biol Phys, 2016 Vol. 96, Issue 2, 341–348
  32. Planas J, Celma A., Placer J., Maldonado X., Trilla E., Salvador C., LLorente D., Regis L., Cuadras M., Carles J., Morote J. Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.” (ref. Acuro-d-16-00024r1), Actas Urol Esp, vol 40, Mayo 2016
  33. Gómez Caamaño A, Zapatero A, López Torrecilla J, Maldonado X. Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain. Clin Transl Oncol Clin Transl Oncol. 2016 Sep;18(9):884-92. doi: 10.1007/s12094-015-1454-0.
  34. Toledo M., Sarria-Estrada S., Quintana M., Maldonado X., Martínez Ricarte F., Rodon J., Auger C., Salas Puig J., Santamaria E., Martínez-Saez E., Prognostic implications of epilepsy in  glioblastomas. Neurology and Neurosurgery 10/2015; 139:166-171. DOI:10.1016/j.clineuro.2015.10.002
  35. Morote J., Maldonado X., Morales R. Cáncer de próstata. Med Clin (Barc). Vol.  146 Núm. 03 Febrero 2016. pii: S0025-7753(15)00041-X. doi: 10.1016/j.medcli.2014.12.021. [Epub ahead of print]
  36. López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, Maldonado X, et al. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. Reports Pract Oncol Radiother [20]. 2015; 259-272
  37. Zapatero A., Guerrero A., Maldonado X., Alvarez A., González Sansegundo C., Cabeza Rodrígue M.A, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cáncer (DART01/05 GICOR): a randomised, controlled, phase III trial. Lancet Oncol 2015, Mar; vol 16, n 3: 320-327
  38. Zapatero A., González Sansegundo C, Boladeras A., Gomez Camaño A., López Torrecilla JL., X.Maldonado.  Androgen deprivation and radiotherapy in patients with prostate cáncer and cardiovascular risk factors: clinical controversies. Clin. Translat.Oncol. 2015; vol 17:223-22
  39. Morote J, Planas J., Maldonado X., Carles J. Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest. Actas Urol 2014; Vol 38, nº10, 419-429,  sept  2014. doi: 10.1016/j.acuroe.2014.06.005. ISSN: 2173-5786
  40. Morales R., Suárez C., Valverde C., Nuñez I., Maldonado X., Morote J., Carles J. Do patients with metastaic urothelial carcinoma benefit fronm docetaxel as second-line chemotherapy?, Clin Translat oncol 2014; 16:102-106
  41. Lopez Torrecilla J., Zapatero A., Herruzo I., Calvo FA., Cabeza MA., Palacios A., Guerrero A., Hervás A., Lara P., Ludeña B., Del Cerro E., Nagore G., Sancho G., Mengual JL, Mira M., Mairiño A., Samper P., Pérez S., Castillo I., Martínez Cedrés JC., Ferrer F., Rodríguez S., Maldonado X., Gómez Caamaño A., Ferrer C. Infraestructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer. Clin Transl Oncol 2014; 16:447-454
  42. Suarez C., Morales R., Ramos V., Núñez I., Valverde C., Planas J., Morote J., Maldonado X., Carles J. Role of Inmunotherapy in castration –resistant prostate cancer (CRPC). BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110.
  43. M.Manson, X.Maldonado, C.Steidle et al.  Neoadjuvant Androgen Deprivation Therapy for volume reduction, lower urinary tract Symptoms relief and quality of life improvement in men with intermediate to high risk Prostate cancer: A randomized Non inferioirty trial of Degarelix versus Goserelin plus bicalutamide. Clinical Oncology 2013 Mar;25(3):190-6.
  44. Vilar S., Maldonado X. Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate BJU Int. 2011 Apr;107(8):1200-8. doi: 10.1111/j.1464-410X.2010.09827.x. Epub 2010 Nov 15
  45. Maldonado X., Sancho G., Ferrer M., Guedea. Revisión crítica del uso de radioterapia como tratamiento inicial del cáncer de próstata localizado. Actas Urológicas Españolas 2010; 34(5): 401-402
  46. Bellmunt J, Orsola A, Maldonado X, Kataja V; Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v134-6. doi: 10.1093/annonc/mdq175
  47. Guedea F., Ramos A., Herruzo I., Sanchez Calzado JA., Contreras J., Romero J., Craven J., Willish P., Torrecilla JL., Maldonado X., et al. Treatment of localised prostate cancer with radiation therapy: evidence versus opinion. Clin Translat Oncol 2010; 12:315-317
  48. Vilar-González S., Maldonado Pijoan X, Andrés Garcia I. Se ha de asumir el efecto de clase farmacológica entre los diferentes análogos de la hormona liberadora de la hormona luteinizante usados en el tratamiento del carinoma de próstata? Actas Urol. Esp 2010; 34(9): 749-757
  49. R.Morales, C.Valverde, Morales R, Valverde C., Rodon J., Pérez J., Maldonado X., Suárez C., Trilla E., Carles J. “Bilateral testicular germ cell tumors- a single hospital experience.. Cli Tranlst Oncol. 2010 (12):299-302
  50. J. Bellmunt, X.Maldonado, A.Orsola. Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.  Annals in Oncology. 2010 (21) V131
  51. Xavier Maldonado. “Post Asco próstata. Novedades en radioterapia”.Tratando juntos el cáncer de próstata. Expert Rev. Anticancer Ther. 30-34, 2007.
  52. Javier Maldonado. “Metodología diagnóstica ante la recidiva bioquímica después de la radioterapia” Arch. Esp. Urol. 59, 10; 1053-1062, 2006
  53. Ana Paula Caresia, Joan Castell-Conesa, Montserrat Negre, Antoni Mestre, Gemma Cuberas, Anabel Mañes*, Xavier Maldonado*. “Thallium -201 Spect Assessment In The Detection Of Recurrences Of Treated Gliomas And Ependymomas”. Clin Translat Oncol. 2006; 8(10): 750-4
  54. Zapatero A., Valcárcel F., Calvo FA., Algas R., Béjar A., Maldonado J., Villá S. Risk-adapted androgen ablation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does Radiation dose influence outcome of patients treated with adjuvant androgen deprivation?. A GICOR study”J Clin Oncol 23:6561-68, 2005
  55. Lozano JD., Maldonado X., Garat M., Giralt J. “Carcinoma de células en anillo de sello de párpado tratado con radioterapia exclusiva” Rev Oncol 2002; 4 (8): 461-2
  56. Giralt J., González J., Del Campo J.M., Maldonado J., Sanz X., Pamias J., Eraso A., Bescós S., Raspall G.“Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx”. Cancer 2000; 89:939-45.
  57. Maldonado X., Alonso J., Giralt J., Cucurella M.G., Del Campo J.M., Rovira A., Felip E., Capellades J., Grivé E., Rubio D., Gili J. “31P magnetic resonance spectroscopy in the assessment of head and neck tumors” International Journal of Radiation Oncology Biology and Physics 1998;40:309-312.
  58. Giralt J., Rubio D., Maldonado X., Naval J., Casado S., Lara F., Roselló J.M., Armengol M. “Fluorouracil and High dose leucovorin with radiotherapy as adjuvant therapy for rectal cancer”. Acta Oncologica 1997;36:51-54.
  59. Del Campo J.M., Felip E., Giralt J., Raspall G., Bescós S., Casado S., Maldonado X.“Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx”. American Journal of clinical Oncology 1997;20:97-100.
  60. Giralt J., Sánchez de Toledo J., Moraga F., Poch J.M., Gallego S., Roselló J., Maldonado X., Prats J.“Improving survival of medulloblastoma: results in two groups of patients”. Oncology 1996;53:38-42.
  61. Ribas A., Bellmunt , Albanell J., Capdevila J.A., Ocaña I., Gallego O., Maldonado J., Giralt J., Solé L.A.“Malignant Lymphoproliferative diseases in HIV-seropositive patients”. Acta Oncologica 1995;34:75-82.
  62. Vergés R., Felip E., Alastuey I., Capdevila F., Maldonado X., Bodi R., Giralt J., Salvador L.“Combined chemotherapy, radiotherapy and surgery in inflammatory breast carcinoma” Acta Oncologica 1995;34:123-125.
  63. Rovirosa A., Bellmunt J., Salud A., Vicente P., Maldonado J., Bodi R., Salvador L. “Endobronchial metastases in colorectal adenocarcinoma”.Tumori 1992;78:270-273
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required